HPV Infection
Conditions
Keywords
Gardasil, Immunogenicity, 9-valent 2-dose HPV vaccination, 9-valent 3-dose HPV vaccination
Brief summary
The goal of this study is to explore and evaluate whether a 2-dose schedule of Gardasil 9 among young and mid-adult women 16-45 years of age is generally safe and immunogenic, with an antibody response that is not inferior to that observed of a 3-dose schedule of Gardasil 9 among women aged 16-26 years old. The investigators thought that having a 2-dose vaccination regimen for individuals 16 to 45 would provide a more robust dataset than those of 27 to 45 years old.
Detailed description
The investigators will identify potential eligible subjects from the Boston Medical Center (BMC) Clinical Data Warehouse from the following BMC clinics: Pediatrics, Adolescent Medicine, Family Medicine, Obstetric/ Gynecology (OB/GYN), and Women's Health/Adult Primary Care. The research team will mail a recruitment opt-out letter signed by the principal investigator to the participant along with a study flyer. The recruitment letter will inform the participant that a research member may contact them via phone within two week to provide more information regarding the study. Participants opting-in will be called and interviewed with the study recruitment script and eligibility will be determined. Eligible participants who agree to participate (in-person or over the phone), will be scheduled to come to the Boston University (BU) General Clinical Research Unit (GCRU) to complete the consent process. At the baseline visit participants will be assigned into the appropriate group (control vs. intervention) based on their age.
Interventions
a 2-dose regimen of Gardasil 9 at 0 and 6 months
DRUGGardasil 9 3 dose regimen
standard 3-dose regimen of Gardasil 9 at 0, 2, 6 months
DRUGGardasil 9 rescue dose
A rescue dose of Gardasil 9 will be given at 12 months
Sponsors
Boston Medical Center
Merck Sharp & Dohme LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
The control group will have 120 subjects will receive a 3-dose regimen as recommended by Center for Disease Control (CDC) given at 0, 2 and 6 months. The intervention group will have 240 subjects who will receive a modified 3-dose regimen given at 0, 6, and 12 months. Both groups will have HPV titers drawn at Visit 1 (pre-vaccination) and Visit 7 (after three doses for the Control group and 2 doses for the Intervention group).
Eligibility
Sex/Gender
FEMALE
Age
16 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Women receiving care at Boston Medical Center
Exclusion criteria
* Currently pregnant * Prior HPV vaccination * A history of severe allergic reaction, including known allergy to any vaccine component, specially severe allergic to yeast * Immunocompromised/previous immunosuppressive therapy * Thrombocytopenia or other coagulation disorder * Currently breastfeeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in immunogenicity of Gardasil 9 | baseline and 7 months | Immunogenicity will be measured by serum antibodies assessed by ELISA to the nine HPV types (anti-HPV 6/11/16/18/31/33/45/ 52/58 where positive anti-HPV serum levels are defined as \>30, \>16, \>20, \>24, \>10, \>8, \>8, \>8, or \>8 milli Merck units (mMU)/mL respectively). |
| Change in geometric mean titers ratios | baseline and 7 months | The geometric mean titers (GMT) ratios will be determined by a post-vaccination geometric mean titer (GMT) ratio with a pre-stated analysis of variance model (95% Confidence Interval lower bound \>0.5). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with HPV seropositivity at day 1 | day 1 | The number of participant who test positive in mili Unit (nMU) which will be will be defined as anti-HPV 6/11/16/18/31/33/45/ 52/58 positive if her anti-HPV serum level is \>30, \>16, \>20, \>24, \>10, \>8, \>8, \>8, or \>8 milli Merck units (mMU)/mL for the 9 types, respectively. The serum testing will be under the direction of Merck research lab. |
| Number of participants with HPV seropositivity at month 7 | month 7 | The number of participant who test positive in mili Unit (nMU) which will be will be defined as anti-HPV 6/11/16/18/31/33/45/ 52/58 positive if her anti-HPV serum level is \>30, \>16, \>20, \>24, \>10, \>8, \>8, \>8, or \>8 milli Merck units (mMU)/mL for the 9 types, respectively. The serum testing will be under the direction of Merck research lab. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORCarl G Streed, MD MPH
Boston Medical Center, Internal Medicine
Outcome results
None listed